Share on StockTwits

DexCom (NASDAQ:DXCM) CEO Terrance H. Gregg unloaded 25,000 shares of DexCom stock on the open market in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $44.24, for a total transaction of $1,106,000.00. Following the completion of the transaction, the chief executive officer now directly owns 395,626 shares of the company’s stock, valued at approximately $17,502,494. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of DexCom (NASDAQ:DXCM) traded down 0.71% during mid-day trading on Friday, hitting $43.62. 451,070 shares of the company’s stock traded hands. DexCom has a 1-year low of $25.49 and a 1-year high of $49.83. The stock’s 50-day moving average is $39. and its 200-day moving average is $38.69. The company’s market cap is $3.292 billion. DexCom also saw unusually large options trading on Tuesday. Investors acquired 168 put options on the company. This is an increase of approximately 118% compared to the average daily volume of 77 put options.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the prior year, the company posted ($0.14) earnings per share. The company’s quarterly revenue was up 64.2% on a year-over-year basis. Analysts expect that DexCom will post $-0.31 EPS for the current fiscal year.

A number of research firms have recently commented on DXCM. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $41.00.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.